{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:18:49Z","timestamp":1773667129521,"version":"3.50.1"},"reference-count":39,"publisher":"American Veterinary Medical Association (AVMA)","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2023,7,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec id=\"sc_a1\">\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>Several phosphodiesterase inhibitors have demonstrable antiplatelet actions when administered to human patients. Concentration-dependent inhibition of feline platelet aggregation by pimobendan has been previously demonstrated in vitro. However, there are no published reports characterizing the effect of oral pimobendan, administered at therapeutic doses, on platelet function in cats. This study aimed to evaluate the effect of orally administered pimobendan on platelet function in healthy adult cats.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sc_a2\">\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>6 healthy purpose-bred adult cats<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sc_a3\">\n<jats:title>METHODS<\/jats:title>\n<jats:p>Cats were administered pimobendan orally at a dosage of 0.625 mg\/cat (low-dose) twice daily for 1 week, followed by 1.25 mg\/cat (high-dose) twice daily for 1 week. Venous blood sampling for platelet testing and plasma drug concentration occurred at baseline, 1 hour postdose on the eighth day of treatment with low-dose pimobendan, 1 hour postdose on the eighth day of treatment with high-dose pimobendan, and after a 1-week washout period. Platelet function was assessed by whole blood aggregometry and by use of a platelet function analyzer (PFA-100\u00ae). Friedman tests were used to compare platelet function parameters among the 4 sampling timepoints.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sc_a4\">\n<jats:title>RESULTS<\/jats:title>\n<jats:p>After 1 week of treatment, median (range) plasma pimobendan concentrations were 15.1 ng\/mL (6.89\u201320.2 ng\/mL) and 32.8 ng\/mL (23.3\u201344.8 ng\/mL) in cats receiving low-dose and high-dose pimobendan, respectively. No significant differences in PFA closure time or any aggregometry variable were found among the treatment conditions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sc_a5\">\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>Pimobendan was not associated with measurable inhibition of platelet function when administered orally to healthy adult cats at 2 clinically relevant dosages.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/ajvr.23.05.0103","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T13:48:07Z","timestamp":1690292887000},"page":"1-7","source":"Crossref","is-referenced-by-count":2,"title":["Effects of orally administered pimobendan on platelet function in healthy adult cats"],"prefix":"10.2460","author":[{"given":"Rebecca","family":"Kennerly","sequence":"first","affiliation":[{"name":"Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda E.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanese L.","family":"Jasper","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA"},{"name":"Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M.","family":"Brainard","sequence":"additional","affiliation":[{"name":"Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"issue":"Suppl 1","key":"B1","series-title":"J Vet Cardiol","first-page":"S318","article-title":"Risk factors associated with sudden death vs. congestive heart failure or arterial thromboembolism in cats with hypertrophic cardiomyopathy","volume":"17","author":"Payne JR","year":"2015","unstructured":"Payne JR, Borgeat K, Brodbelt DC, Connolly DJ, Luis Fuentes V. Risk factors associated with sudden death vs. congestive heart failure or arterial thromboembolism in cats with hypertrophic cardiomyopathy. J Vet Cardiol. 2015;17(Suppl 1):S318\u2013S328. doi:10.1016\/j.jvc.2015.09.008"},{"key":"B2","series-title":"J Am Vet Med Assoc","first-page":"202","article-title":"Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990\u20131999)","volume":"220","author":"Rush JE","year":"2002","unstructured":"Rush JE, Freeman LM, Fenollosa NK, et al. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990\u20131999). J Am Vet Med Assoc. 2002;220:202\u2013207. doi:10.2460\/javma.2002.220.202"},{"key":"B3","series-title":"Br J Clin Pharmacol","first-page":"634","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele P","year":"2011","unstructured":"Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011;72:634\u2013646. doi:10.1111\/j.1365-2125.2011.04034.x"},{"key":"B4","series-title":"Handb Exp Pharmacol","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-642-29423-5_9","article-title":"Targeting phosphodiesterases in anti-platelet therapy","author":"Rondina MT","year":"2012","unstructured":"Rondina MT, Weyrich AS. Targeting phosphodiesterases in anti-platelet therapy. Handb Exp Pharmacol. 2012:225\u2013238."},{"key":"B5","series-title":"Biochem Pharmacol","first-page":"1153","article-title":"Taming platelets with cyclic nucleotides","volume":"62","author":"Schwarz UR","year":"2001","unstructured":"Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol. 2001;62:1153\u20131161. doi:10.1016\/S0006-2952(01)00760-2"},{"key":"B6","series-title":"Thromb Haemost","first-page":"873","article-title":"Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases","volume":"87","author":"Manns JM","year":"2002","unstructured":"Manns JM, Brenna KJ, Colman RW, et al. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases. Thromb Haemost. 2002;87:873\u2013879. doi:10.1055\/s-0037-1613099"},{"key":"B7","series-title":"Thromb Haemost","first-page":"333","article-title":"Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells","volume":"56","author":"Eldor A","year":"1986","unstructured":"Eldor A, Vlodavsky I, Fuks Z, et al. Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells. Thromb Haemost. 1986;56:333\u2013339. doi:10.1055\/s-0038-1661678"},{"key":"B8","series-title":"Thromb Res","first-page":"909","article-title":"A comparison of the effects of three positive inotropic agents (amrinone, milrinone and medorinone) on platelet aggregation in human whole blood","volume":"57","author":"Pattison A","year":"1990","unstructured":"Pattison A, Astley N, Eason CT, et al. A comparison of the effects of three positive inotropic agents (amrinone, milrinone and medorinone) on platelet aggregation in human whole blood. Thromb Res. 1990;57:909\u2013918. doi:10.1016\/0049-3848(90)90157-8"},{"key":"B9","series-title":"Gen Pharmacol","first-page":"1149","article-title":"Interplay between milrinone and adenosine in the inhibition of human platelet response","volume":"27","author":"Anfossi G","year":"1996","unstructured":"Anfossi G, Massucco P, Piretto V, et al. Interplay between milrinone and adenosine in the inhibition of human platelet response. Gen Pharmacol. 1996;27:1149\u20131154. doi:10.1016\/S0306-3623(96)00050-X"},{"key":"B10","series-title":"Br J Clin Pharmacol","first-page":"179","article-title":"Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo","volume":"30","author":"Muller TH","year":"1990","unstructured":"Muller TH, Su CA, Weisenberger H, et al. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol. 1990;30:179\u2013186. doi:10.1111\/j.1365-2125.1990.tb03763.x"},{"key":"B11","series-title":"Thromb Res","first-page":"227","article-title":"Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study","volume":"71","author":"Barradas MA","year":"1993","unstructured":"Barradas MA, Jagroop A, O\u2019Donoghue S, et al. Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study. Thromb Res. 1993;71:227\u2013236. doi:10.1016\/0049-3848(93)90097-8"},{"issue":"6","key":"B12","series-title":"J Vet Intern Med","first-page":"1765","article-title":"Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study- a randomized clinical trial","volume":"30","author":"Boswood A","year":"2016","unstructured":"Boswood A, Haggstrom J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study- a randomized clinical trial. J Vet Intern Med. 2016;30(6):1765. doi:10.1111\/jvim.14586"},{"issue":"6","key":"B13","series-title":"J Vet Intern Med","first-page":"1441","article-title":"Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST Study","volume":"27","author":"Haggstrom J","year":"2013","unstructured":"Haggstrom J, Boswood A, O\u2019Grady M, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST Study. J Vet Intern Med. 2013;27(6):1441. doi:10.1111\/jvim.12181"},{"key":"B14","series-title":"J Vet Intern Med","first-page":"1337","article-title":"Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy: the PROTECT study","volume":"26","author":"Summerfield NJ","year":"2012","unstructured":"Summerfield NJ, Boswood A, O\u2019Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy: the PROTECT study. J Vet Intern Med. 2012;26:1337\u20131349. doi:10.1111\/j.1939-1676.2012.01026.x"},{"key":"B15","series-title":"J Am Vet Med Assoc","first-page":"534","article-title":"Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure","volume":"245","author":"Reina-Doreste Y","year":"2014","unstructured":"Reina-Doreste Y, Stern JA, Keene BW, et al. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. J Am Vet Med Assoc. 2014;245:534\u2013539. doi:10.2460\/javma.245.5.534"},{"key":"B16","series-title":"J Am Vet Med Assoc","first-page":"89","article-title":"Effect of oral administration of pimobendan in cats with heart failure","volume":"241","author":"Gordon SG","year":"2012","unstructured":"Gordon SG, Saunders AB, Roland RM, et al. Effect of oral administration of pimobendan in cats with heart failure. J Am Vet Med Assoc. 2012;241:89\u201394. doi:10.2460\/javma.241.1.89"},{"key":"B17","series-title":"Bioorg Med Chem Lett","first-page":"1575","article-title":"Pyridazines. Part 28: 5-alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors","volume":"12","author":"Sotelo E","year":"2002","unstructured":"Sotelo E, Fraiz N, Yanez M, et al. Pyridazines. Part 28: 5-alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors. Bioorg Med Chem Lett. 2002;12:1575\u20131577. doi:10.1016\/S0960-894X(02)00246-9"},{"key":"B18","series-title":"Cardiovasc Res","first-page":"184","article-title":"Platelet aggregation inhibitory effects of the new positive inotropic agents pimobendan and UD CG 212 in whole blood","volume":"23","author":"Saniabadi AR","year":"1989","unstructured":"Saniabadi AR, Lowe GD, Belch JJ, et al. Platelet aggregation inhibitory effects of the new positive inotropic agents pimobendan and UD CG 212 in whole blood. Cardiovasc Res. 1989;23:184\u2013190. doi:10.1093\/cvr\/23.3.184"},{"key":"B19","series-title":"Am J Vet Res","first-page":"403","article-title":"In vitro effect of pimobendan on platelet aggregation in dogs","volume":"74","author":"Shipley EA","year":"2013","unstructured":"Shipley EA, Hogan DF, Fiakpui NN, et al. In vitro effect of pimobendan on platelet aggregation in dogs. Am J Vet Res. 2013;74:403\u2013407. doi:10.2460\/ajvr.74.3.403"},{"key":"B20","series-title":"Arzneimittelforschung","first-page":"1389","article-title":"Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock","volume":"38","author":"Bitterman H","year":"1988","unstructured":"Bitterman H, Smith BA, Lefer AM. Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock. Arzneimittelforschung. 1988;38:1389\u20131393."},{"key":"B21","series-title":"J Vet Cardiol","first-page":"310","article-title":"Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats","volume":"18","author":"Yata M","year":"2016","unstructured":"Yata M, McLachlan AJ, Foster DJ, et al. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats. J Vet Cardiol. 2016;18:310\u2013325. doi:10.1016\/j.jvc.2016.07.001"},{"key":"B22","series-title":"J Vet Cardiol","first-page":"489","article-title":"Pharmacokinetics of oral pimobendan in healthy cats","volume":"14","author":"Hanzlicek AS","year":"2012","unstructured":"Hanzlicek AS, Gehring R, Kukanich B, et al. Pharmacokinetics of oral pimobendan in healthy cats. J Vet Cardiol. 2012;14:489\u2013496. doi:10.1016\/j.jvc.2012.06.002"},{"issue":"4","key":"B23","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"398","article-title":"A review of the pharmacology and clinical uses of pimobendan","volume":"22","author":"Boyle KL","year":"2012","unstructured":"Boyle KL, Leech E. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care (San Antonio). 2012;22(4):398\u2013408 doi:10.1111\/j.1476-4431.2012.00768.x"},{"key":"B24","article-title":"Pimobendan and heart disease","author":"Saunders AB","year":"2018","unstructured":"Saunders AB, Gordon SG. Pimobendan and heart disease. Today\u2019s Veterinary Practice. June 8, 2018. Accessed January 14, 2023. https:\/\/todaysveterinarypractice.com\/pharmacology\/pimobendan-and-heart-disease\/"},{"key":"B25","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"99","article-title":"Lack of inhibitory effect of acetylsalicylic acid and meloxicam on whole blood platelet aggregation in cats","volume":"22","author":"Cathcart CJ","year":"2012","unstructured":"Cathcart CJ, Brainard BM, Reynolds LR, et al. Lack of inhibitory effect of acetylsalicylic acid and meloxicam on whole blood platelet aggregation in cats. J Vet Emerg Crit Care (San Antonio). 2012;22:99\u2013106."},{"issue":"3","key":"B26","series-title":"J Vet Diagn Invest","first-page":"352","article-title":"Assessment of platelet function in healthy sedated cats using three whole blood platelet function tests","volume":"27","author":"Ho K","year":"2015","unstructured":"Ho K, Abrams-Ogg ACG, Wood RD, O\u2019Sullivan ML, Kirby GM, Blois SL. Assessment of platelet function in healthy sedated cats using three whole blood platelet function tests. J Vet Diagn Invest. 2015;27(3):352\u2013360. doi:10.1177\/1040638715584994"},{"key":"B27","series-title":"Res Vet Sci","first-page":"149","article-title":"Influence of a low dosage of clopidogrel on platelet function in cats as measured by the platelet function analyser PFA-100 and the multiplate analyser","volume":"109","author":"Teuber M","year":"2016","unstructured":"Teuber M, Mischke R. Influence of a low dosage of clopidogrel on platelet function in cats as measured by the platelet function analyser PFA-100 and the multiplate analyser. Res Vet Sci. 2016;109:149\u2013156. doi:10.1016\/j.rvsc.2016.09.011"},{"issue":"1","key":"B28","series-title":"Vet Q","first-page":"8","article-title":"Effects of clopidogrel therapy on whole blood platelet aggregation, the Plateletworks assay and coagulation parameters in cats with asymptomatic hypertrophic cardiomyopathy: a pilot study","volume":"37","author":"den Toom ML","year":"2016","unstructured":"den Toom ML, van Leeuwen MW, Szatm\u00e1ri V, Teske E. Effects of clopidogrel therapy on whole blood platelet aggregation, the Plateletworks assay and coagulation parameters in cats with asymptomatic hypertrophic cardiomyopathy: a pilot study. Vet Q. 2016;37(1):8\u201315. doi:10.1080\/01652176.2016.1244618"},{"issue":"5","key":"B29","series-title":"Exp Toxicol Pathol","first-page":"637","article-title":"Optimization of Multiplate(\u00ae) whole blood platelet aggregometry in the Beagle dog and Wistar rat for ex vivo drug toxicity testing","volume":"65","author":"Defontis M","year":"2013","unstructured":"Defontis M, C\u00f4t\u00e9 S, Stirn M, Ledieu D. Optimization of Multiplate(\u00ae) whole blood platelet aggregometry in the Beagle dog and Wistar rat for ex vivo drug toxicity testing. Exp Toxicol Pathol. 2013;65(5):637\u2013644. doi:10.1016\/j.etp.2012.07.003"},{"issue":"8","key":"B30","series-title":"Platelets","first-page":"730","article-title":"Assessment of multiplate platelet aggregometry using citrate, heparin or hirudin in Rhesus macaques","volume":"26","author":"Dugan G","year":"2015","unstructured":"Dugan G, O\u2019Donnell L, Hanbury DB, Cline JM, Caudell DL. Assessment of multiplate platelet aggregometry using citrate, heparin or hirudin in Rhesus macaques. Platelets. 2015;26(8):730\u2013735. doi:10.3109\/09537104.2014.988694"},{"issue":"5","key":"B31","series-title":"Platelets","first-page":"359","article-title":"Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions","volume":"23","author":"Kaiser AF","year":"2012","unstructured":"Kaiser AF, Neubauer H, Franken CC, Kr\u00fcger JC, M\u00fcgge A, Meves SH. Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions. Platelets. 2012;23(5):359\u2013367. doi:10.3109\/09537104.2011.624211"},{"issue":"1","key":"B32","series-title":"Platelets","first-page":"7","article-title":"The effect of ex vivo anticoagulants on whole blood platelet aggregation","volume":"20","author":"Kalb ML","year":"2009","unstructured":"Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets. 2009;20(1):7\u201311. doi:10.1080\/09537100802364076"},{"issue":"2","key":"B33","series-title":"Vet J","first-page":"144","article-title":"Measurement of platelet function in dogs using a novel impedance aggregometer","volume":"185","author":"Kalbantner K","year":"2010","unstructured":"Kalbantner K, Baumgarten A, Mischke R. Measurement of platelet function in dogs using a novel impedance aggregometer. Vet J. 2010;185(2):144\u2013151. doi:10.1016\/j.tvjl.2009.05.028"},{"issue":"1","key":"B34","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"107","article-title":"Evaluation of platelet aggregometry in dogs using the Multiplate platelet analyzer: impact of anticoagulant choice and assay duration [published correction appears in J Vet Emerg Crit Care (San Antonio). 2013 Nov-Dec;23(6):670]","volume":"22","author":"Marschner CB","year":"2012","unstructured":"Marschner CB, Kristensen AT, Spodsberg EH, Wiinberg B. Evaluation of platelet aggregometry in dogs using the Multiplate platelet analyzer: impact of anticoagulant choice and assay duration [published correction appears in J Vet Emerg Crit Care (San Antonio). 2013 Nov-Dec;23(6):670]. J Vet Emerg Crit Care (San Antonio). 2012;22(1):107\u2013115. doi:10.1111\/j.1476-4431.2011.00709.x"},{"issue":"4","key":"B35","series-title":"Vet Clin Pathol","first-page":"385","article-title":"Platelet function in clinically healthy cats and cats with hypertrophic cardiomyopathy using the Platelet Function Analyzer-100","volume":"37","author":"Jandry KE","year":"2008","unstructured":"Jandry KE, Norris JW, MacDonald KA, Kittleson MD, Tablin F. Platelet function in clinically healthy cats and cats with hypertrophic cardiomyopathy using the Platelet Function Analyzer-100. Vet Clin Pathol. 2008;37(4):385\u2013388. doi:10.1111\/j.1939-165X.2008.00062.x"},{"issue":"9","key":"B36","series-title":"J Am Vet Med Assoc","first-page":"1406","article-title":"Antiplatelet effects and pharmacodynamics of clopidogrel in cats","volume":"225","author":"Hogan DF","year":"2004","unstructured":"Hogan DF, Andrews DA, Green HW, Talbott KK, Ward MP, Calloway BM. Antiplatelet effects and pharmacodynamics of clopidogrel in cats. J Am Vet Med Assoc. 2004;225(9):1406\u20131411. doi:10.2460\/javma.2004.225.1406"},{"issue":"5","key":"B37","series-title":"J Vet Intern Med","first-page":"1619","article-title":"Platelet activation and clopidogrel effects on ADP-induced platelet activation in cats with or without the A31P mutation in MYBPC3","volume":"30","author":"Li RH","year":"2016","unstructured":"Li RH, Stern JA, Ho V, Tablin F, Harris SP. Platelet activation and clopidogrel effects on ADP-induced platelet activation in cats with or without the A31P mutation in MYBPC3. J Vet Intern Med. 2016;30(5):1619\u20131629. doi:10.1111\/jvim.14568"},{"key":"B38","series-title":"J Vet Intern Med","first-page":"411","article-title":"Platelet activation in cats with hypertrophic cardiomyopathy","volume":"28","author":"Tablin F","year":"2014","unstructured":"Tablin F, Schumacher T, Pombo M, et al. Platelet activation in cats with hypertrophic cardiomyopathy. J Vet Intern Med. 2014;28:411\u2013418. doi:10.1111\/jvim.12325"},{"issue":"5","key":"B39","series-title":"Am J Vet Res","first-page":"619","article-title":"Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease","volume":"55","author":"Welles EG","year":"1994","unstructured":"Welles EG, Boudreaus MK, Crager CS, Tyler JW. Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease. Am J Vet Res. 1994;55(5):619\u2013627."}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/aop\/ajvr.23.05.0103\/ajvr.23.05.0103.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/aop\/ajvr.23.05.0103\/ajvr.23.05.0103.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/aop\/ajvr.23.05.0103\/ajvr.23.05.0103.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T13:48:29Z","timestamp":1690292909000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/aop\/ajvr.23.05.0103\/ajvr.23.05.0103.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2460\/ajvr.23.05.0103","relation":{},"ISSN":["0002-9645","1943-5681"],"issn-type":[{"value":"0002-9645","type":"print"},{"value":"1943-5681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]}}}